ORGS - オ―ジェネシス （Orgenesis Inc.） オ―ジェネシスORGSのチャート
ORGSの企業情報
| symbol | ORGS |
|---|---|
| 会社名 | Orgenesis Inc （オ―ジェネシス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Orgenesis Inc. is a regenerative therapy company. The Company operates through two segments: Contract Development and Manufacturing Organization (CDMO) and Cellular Therapy Business (CTB). The CDMO activity is operated by the Company's subsidiary MaSTherCell SA which specializes in cell therapy development for advanced medicinal products. MaSTherCell is providing two types of services to its customers: process and assay development services and good manufacturing practice (GMP) contract manufacturing services. The CTB activity is based on its technology that demonstrates the capacity to induce a shift in the developmental fate of cells from the liver and differentiating (converting) them into pancreatic beta cell-like insulin producing cells for patients with Type I Diabetes. It intends to advance a product that combines cell-based therapy and regenerative medicine Autologous Insulin Producing (AIP) cells into clinical development. オ―ジェネシスは米国のバイオ医薬品企業。臨床段階で、糖尿病のトランス分化技術の開発・商業化に従事する。肝臓からの細胞発達の変化を促し、糖尿病1型患者の膵臓のベ―タ細胞のようなインスリン生産細胞に分化する技術に基づく細胞治療が含まれる。また、他の細胞治療に焦点を当てる事業も展開する。本社所在地はメリ―ランド州ジャ―マンタウン。 Orgenesis is a global biotech company working to unlock the full potential of cell and gene therapies (CGTs) in an affordable and accessible format at the point of care. The Orgenesis POCare Platform is comprised of three enabling components: a pipeline of licensedPOCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. Orgenesis identifies promising new therapies and leverages its POCare Platform to provide a rapid, globally harmonized pathway for these therapies to reach and treat large numbers of patients at lowered costs through efficient, scalable, and decentralized production. The POCare Network brings together patients, doctors, industry partners, research institutes and hospitals worldwide to achieve harmonized, regulated clinical development and production of the therapies. |
| 本社所在地 | 20271 Goldenrod Lane Germantown MD 20876 USA |
| 代表者氏名 | Vered Caplan ヴェードキャプラン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer President; Chief Executive Officer of Orgenesis Maryland Inc. |
| 電話番号 | +1 480-659-6404 |
| 設立年月日 | 39600 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 103人 |
| url | www.orgenesis.com |
| nasdaq_url | https://www.nasdaq.com/symbol/orgs |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -5.41200 |
| 終値（lastsale） | 6.63 |
| 時価総額（marketcap） | 96594850.17 |
| 時価総額 | 時価総額（百万ドル） 96.85145 |
| 売上高 | 売上高（百万ドル） 16.23000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 82.92945 |
| 当期純利益 | 当期純利益（百万ドル） -14.15100 |
| 決算概要 | 決算概要 BRIEF: For the nine months ended 31 August 2018 Orgenesis Inc revenues increased 91% to $12.9M. Net loss applicable to common stockholders increased 26% to $13.3M. Revenues reflect CDMO segment increase from $4.7M to $23.5M CTB segment increase from $0K to $83K. Higher net loss reflects CTB segment loss increase from $6M to $14M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.11 to -$1.07. |
ORGSのテクニカル分析
ORGSのニュース
Why Orgenesis Stock Is Getting Hammered Thursday 2023/02/23 17:11:32 Benzinga
Orgenesis Inc (NASDAQ: ORGS ) shares are trading lower by 29.95% to $1.45 Thursday morning after the company announced pricing of a $3.7 million registered direct offering. What Else? Orgenesis today announced that it has entered into a securities purchase agreement with institutional investors for the purchase and sale … Full story available on Benzinga.com
Orgenesis stock sinks ~31% after launching offering to raise $3.7M (NASDAQ:ORGS) 2023/02/23 16:57:41 Seeking Alpha
Shares of biotech company Orgenesis (ORGS) slumped nearly 31% to a daily low of $1.43 on Thursday after announcing stock and warrants offering to raise $3.7 million.
Orgenesis Announces Pricing of $3.7 Million Registered Direct Offering of Common Stock, Warrants 2023/02/23 14:59:04 Investing.com
https://www.investing.com/news/assorted/orgenesis-announces-pricing-of-37-million-registered-direct-offering-of-common-stock-warrants-432SI-3012536
Orgenesis''s Return On Capital Employed Insights 2022/12/22 14:46:56 Benzinga
According to data from Benzinga Pro, during Q3, Orgenesis ''s (NASDAQ: ORGS ) reported sales totaled $7.84 million. Despite a 74.36% increase in earnings, the company posted a loss of $1.41 million. In Q2, Orgenesis brought in $7.20 million in sales but lost $5.49 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Orgenesis PT Lowered to $6 at Benchmark 2022/11/23 12:22:01 Investing.com
https://www.investing.com/news/pro/orgenesis-pt-lowered-to-6-at-benchmark-432SI-2950745
Orgenesis''s Return On Capital Employed Insights 2022/12/22 14:46:56 Benzinga
According to data from Benzinga Pro, during Q3, Orgenesis ''s (NASDAQ: ORGS ) reported sales totaled $7.84 million. Despite a 74.36% increase in earnings, the company posted a loss of $1.41 million. In Q2, Orgenesis brought in $7.20 million in sales but lost $5.49 million in earnings. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
Orgenesis PT Lowered to $6 at Benchmark 2022/11/23 12:22:01 Investing.com
https://www.investing.com/news/pro/orgenesis-pt-lowered-to-6-at-benchmark-432SI-2950745
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday 2022/11/14 07:35:17 Benzinga
Gainers ShiftPixy, Inc. (NASDAQ: PIXY ) shares surged 56.6% to settle at $19.10 on Friday. Shares of several companies in the broader industrial space traded higher on continued hopes of softer Fed policy after CPI this week showed October inflation below estimates. Exela Technologies, Inc. (NASDAQ: XELA ) gained 50.3% to close at $0.2780. The company is expected to report Q3 results on November 14, 2022. uCloudlink Group Inc. (NASDAQ: UCL ) jumped 49.6% to close at $1.90. uCloudlink Group is expected to report Q3 financial results on November 16, 2022. Core Scientific, Inc. (NASDAQ: CORZ ) gained 44.3% to settle at $0.1981. Compass, Inc. (NYSE: COMP ) jumped 44% to close at $3.50. Compass posted a wider-than-expected loss for its third quarter, while sales topped estimates. Kaleyra, Inc. (NYSE: KLR ) climbed 38.5% to close at $0.90. Kaleyra extended Oracle partnership to leverage Oracle Cloud. Nutex Health Inc. (NASDAQ: NUTX ) gained 37.7% to close at $1.16. MiNK Therapeutics, Inc. (NASDAQ: INKT ) jumped 35.8% to close at $3.00.
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript 2022/11/14 02:29:02 Seeking Alpha
Orgenesis (NASDAQ:NASDAQ:ORGS) Q3 2022 Earnings Conference Call November 11, 2022 08:00 ET Company Participants David Waldman - Investor Relations Vered Caplan - Chief Executive Officer…
Orgenesis GAAP EPS of $0.05 2022/11/10 22:56:05 Seeking Alpha
Orgenesis press release (ORGS): Q3 GAAP EPS of $0.05.Cash and cash equivalents of $3.01M
Volume - Orgenesis Inc. Short Interest Up 52.4% in May 2022/06/14 21:41:09 Business Mag
Orgenesis Inc. saw a significant increase in short interest in May. As of May 31st, there was short interest totalling 215,400 shares, an increase of 52.4% from the May 15th…
Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight 2022/05/18 17:00:00 Benzinga
New York, USA, May 18, 2022 (GLOBE NEWSWIRE) -- Oncolytic Virus Cancer Therapy Pipeline Shows Rapid Progress in Clinical Trials, Assesses DelveInsight Oncolytic Virus Cancer Therapy Pipeline involves 70+ key companies continuously working towards developing 100+ Oncolytic Virus Cancer therapies, as per DelveInsight DelveInsight''s '' Oncolytic Virus Cancer Therapy Pipeline Insight 2022 '' report provides comprehensive global coverage of available, marketed, and pipeline Oncolytic Virus Cancer Therapy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Oncolytic Virus Cancer Therapy pipeline domain. Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report DelveInsight''s Oncolytic Virus Cancer Therapy Pipeline report depicts a robust space with 70+ active players working to develop 100+ pipeline therapies for Oncolytic Viruses Cancer treatment. Leading Oncolytic Virus Cancer Therapy companies such as Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc.
Orgenesis to raise $14.8M in stock and warrants offering 2022/03/31 12:04:54 Seeking Alpha
Orgenesis (ORGS) entered into a definitive securities purchase agreement with certain investors for the sale of 4.9M shares in a private placement at $3/share and warrants to purchase up…